Physician profile
Thomas E Masullo
NPI 1821756057
$884.76
in general payments reported to CMS, 2019-2025
15 companies · $419 in 2025
The $419 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $36.95 · 2024: $429 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $848 · Education: $36.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $847.81 |
| Education | $36.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $148.33 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $144.65 | 2024-2025 | Rexulti, Abilify Mycite |
| Axsome Therapeutics, INC. | $101.33 | 2024-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $85.90 | 2024-2025 | Cobenfy |
| Tris Pharma INC | $76.65 | 2024-2025 | Dyanavel Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $67.64 | 2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $52.04 | 2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $36.95 | 2023 | Invega Sustenna |
| Corium, LLC | $36.19 | 2024 | Azstarys |
| Lundbeck LLC | $31.02 | 2024-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $30.54 | 2024 | Trintellix |
| Neuronetics, INC. | $21.86 | 2024 | Neurostar Tms Therapy System |
| Sage Therapeutics, LLC | $18.49 | 2024 | |
| Alkermes, INC. | $18.38 | 2025 | Vivitrol |
| Neos Therapeutics, Lp | $14.79 | 2024 | Cotempla Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Masullo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.